A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > REGULATORY
REGULATORY
- MHLW Issues Notification for Precautions in Use of Methapain
October 4, 2012
- Minister of Health Mitsui Sees Need for Cross-Agency Efforts to Promote New Drug Development
October 4, 2012
- MHLW to Enhance Drug Review System to Eliminate Application Lag: PFSB Director Gen. Ebata
October 3, 2012
- Committee to Discuss Basic Policy for Improving Safety and Supply of Blood Products for Its Revision in FY2013
October 3, 2012
- MHLW Issues Improvement Order to Benesis Due to Tampering of Packaging Boxes after Permitting Shipment
October 2, 2012
- Pharmacist Mitsui Becomes Health Minister, Industry Hails Appointment
October 2, 2012
- MHLW Approves 26 Products Including Novartis’s Seebri
October 2, 2012
- Perpetuation of Premium for New Drug Development Will Depend on Convincing Data: HIB Director General Kikura
October 2, 2012
- Study Group Outlines Plan to Establish Palliative Care Centers at Designated Cancer Treatment Alliance Hospitals
October 1, 2012
- MHLW Reports Package Insert Revisions for Elplat
September 28, 2012
- Price Gap between Long-Listed Products, Generics Should Be Retained: Mr Chikazawa of MHLW
September 28, 2012
- MHLW Asks FPMAJ to Revise Precaution Section of Package Inserts for 13 APIs Including Diclofenac
September 28, 2012
- HSB to Make “Steady Efforts” Against Lifestyle Diseases: Director General Yajima
September 28, 2012
- Latest Proposal to Discuss Reference Pricing System Gets Cold Shoulder from CSIMC
September 26, 2012
- MHLW Reports 1 Dispensing Error Due to Name Similarity; Almarl Already Renamed
September 24, 2012
- MHLW Issues Notification to Prohibit Dispensing Point Services
September 21, 2012
- MHLW to Introduce Brand Name Rules for Combination Injectables to Prevent Medical Accidents
September 21, 2012
- Reimbursement of Generic Drugs Used Off-Label “Not Necessarily Illegal,” Government Says
September 20, 2012
- Half of Hospitals Participating in Network Play Central Role: MHLW FY2011 Survey
September 19, 2012
- MHLW Eyes Introduction of Piecework Payment for Clinical Trials at 54 Hospitals by FY2016
September 18, 2012
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…